See more : BrightSpring Health Services, Inc. Common Stock (BTSG) Income Statement Analysis – Financial Results
Complete financial analysis of CHORDIA THERAPEUTICS INC (190A.T) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of CHORDIA THERAPEUTICS INC, a leading company in the Pharmaceutical industry within the None sector.
- artnet AG (ART.DE) Income Statement Analysis – Financial Results
- E Kocref Cr-Reit (088260.KS) Income Statement Analysis – Financial Results
- VBI (4170.TWO) Income Statement Analysis – Financial Results
- Acadian Timber Corp. (ADN.TO) Income Statement Analysis – Financial Results
- The Bombay Dyeing and Manufacturing Company Limited (BOMDYEING.NS) Income Statement Analysis – Financial Results
CHORDIA THERAPEUTICS INC (190A.T)
Industry: Pharmaceutical
About CHORDIA THERAPEUTICS INC
Chordia is focused on the oncology area, with its target areas ranging from exploratory research to Proof of Concept (POC). For subsequent business development, we will build a system that allows us to make the best choices for maximizing corporate value, such as out-licensing and joint development and sales.
| Metric | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
| Revenue | 0.00 | 2.50B | 0.00 | 800.00M |
| Cost of Revenue | 4.09M | 0.00 | 3.15M | 0.00 |
| Gross Profit | -4.09M | 2.50B | -3.15M | 800.00M |
| Gross Profit Ratio | 0.00% | 100.00% | 0.00% | 100.00% |
| Research & Development | 1.50B | 2.00B | 1.66B | 1.22B |
| General & Administrative | 0.00 | 0.00 | -3.15M | -700.00K |
| Selling & Marketing | 0.00 | 0.00 | 188.00M | 171.44M |
| SG&A | 297.51M | 285.08M | 184.85M | 170.74M |
| Other Expenses | 0.00 | 0.00 | 55.49M | 162.86M |
| Operating Expenses | 1.80B | 2.28B | 1.84B | 1.39B |
| Cost & Expenses | 1.80B | 2.29B | 1.84B | 1.39B |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 4.09M | 6.04M | 3.15M | 700.00K |
| EBITDA | -1.82B | 218.10M | -1.77B | -687.06M |
| EBITDA Ratio | 0.00% | 8.72% | 0.00% | -73.37% |
| Operating Income | -1.80B | 212.06M | -1.84B | -587.67M |
| Operating Income Ratio | 0.00% | 8.48% | 0.00% | -73.46% |
| Total Other Income/Expenses | -23.31M | 13.70M | 67.48M | 169.19M |
| Income Before Tax | -1.82B | 225.76M | -1.78B | -525.21M |
| Income Before Tax Ratio | 0.00% | 9.03% | 0.00% | -65.65% |
| Income Tax Expense | 2.42M | 2.42M | 2.42M | 1.90M |
| Net Income | -1.83B | 223.34M | -1.78B | -527.11M |
| Net Income Ratio | 0.00% | 8.93% | 0.00% | -65.89% |
| EPS | -31.11 | 3.96 | -39.78 | -15.08 |
| EPS Diluted | -31.11 | 3.96 | -39.78 | -15.08 |
| Weighted Avg Shares Out | 58.73M | 56.44M | 44.72M | 34.95M |
| Weighted Avg Shares Out (Dil) | 58.73M | 56.44M | 44.72M | 34.95M |
Source: https://incomestatements.info
Category: Stock Reports